AstraZeneca in Orchid tie-in
AstraZeneca is to collaborate in genetic research with America's Orchid BioSciences in an effort to personalise drugs.
Separately, Orchid agreed to buy AstraZeneca's Cellmark Diagnostics, a genetic testing unit, for an undisclosed sum. AstraZeneca shares rose 34p to 3075p.
- The Frankenstein car you probably don't want: Professor...
- Has the big weekly shop had its day? Singletons and couples...
- 'I earned £9k by "spotting" an empty home': How buyers,...
- Strictly a rip-off: Mobile operators hit customers with 80%...
- Harsh winter predictions push up used 4x4 prices already -...
- Diary of a Private Investor: Beaten-up BP's near-8%...
- Energy saving tips: Should you turn off radiators in rooms...
- I badly need the £25k I tied up in a three-year bond but...
- Can Vauxhall's all-new Astra defeat Britain's favourite Ford...
- Black Friday sales forecast to top £1bn but experts warn...
- MIDAS SHARE TIPS: Make a killing on Redcentric - a firm that...
- Nectar profits fall £60m despite rising sales as canny...